Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2

The aim was to evaluate emtricitabine (FTC) and tenofovir (TFV) neonatal ingestion through breast milk. Median TFV and FTC breast milk doses represented 0.03% and 2%, respectively, of the proposed oral infant doses. Neonatal simulated plasma concentrations were extremely low for TFV but between the...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2011-03, Vol.55 (3), p.1315-1317
Main Authors: Benaboud, Sihem, Pruvost, Alain, Coffie, Patrick A, Ekouévi, Didier K, Urien, Saïk, Arrivé, Elise, Blanche, Stéphane, Théodoro, Frédéric, Avit, Divine, Dabis, François, Tréluyer, Jean-Marc, Hirt, Déborah
Format: Article
Language:English
Subjects:
Adenine
Anti-HIV Agents
Antiviral Agents
Deoxycytidine
Milk, Human
Organophosphonates
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim was to evaluate emtricitabine (FTC) and tenofovir (TFV) neonatal ingestion through breast milk. Median TFV and FTC breast milk doses represented 0.03% and 2%, respectively, of the proposed oral infant doses. Neonatal simulated plasma concentrations were extremely low for TFV but between the half-maximal inhibitory concentration and the adult minimal expected concentration for FTC. The rare children who will acquire HIV despite TDF-FTC therapy will need to be monitored for viral resistance acquisition.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00514-10